1. FDA news release. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment. Content current as of 01/06/2023. Accessed January 11, 2023.
2. Eisai Co., Ltd. Eisai's Approach to U.S. Pricing for Leqembi™ (Lecanemab), a Treatment for Early Alzheimer's Disease, Sets Forth Our Concept of "Societal Value of Medicine" in Relation to "Price of Medicine" [media release]. 07 Jan 2023. https://www.eisai.com/.
3. Lecanemab in early Alzheimer's disease;van Dyck;N Engl J Med,2023
4. Eisai Co., Ltd. Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe [media release]. 11 Jan 2023. https://www.eisai.com/.